Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine
- 1 August 2001
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 114 (2) , 349-357
- https://doi.org/10.1111/j.1365-2141.2001.02933.x
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndromeLeukemia, 1997
- The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup studyAnnals of Hematology, 1992
- Age‐related incidence and other epidemiological aspects of myelodysplastic syndromesBritish Journal of Haematology, 1992
- The effect of 1‐hydroxyvitamin D3 for prolongation of leukemic transformation‐free survival in myelodysplastic syndromesAmerican Journal of Hematology, 1991
- Disappearance of Trisomy 8 after Alpha-2 Interferon in a Patient with Myelodysplastic SyndromeNew England Journal of Medicine, 1988
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982
- Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant DataJournal of the American Statistical Association, 1974
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958